Welcome to our dedicated page for Terns Pharmaceuticals news (Ticker: TERN), a resource for investors and traders seeking the latest updates and insights on Terns Pharmaceuticals stock.
Terns Pharmaceuticals, Inc. (Nasdaq: TERN) is a clinical-stage biopharmaceutical company with a mission to innovate and develop small-molecule, molecularly-targeted, oral therapies for the treatment of serious diseases, including liver diseases and cancers. Based in San Mateo, California and Shanghai, Terns leverages its expertise in disease biology and medicinal chemistry to advance its growing pipeline of drugs aimed at addressing significant unmet medical needs globally.
The company is renowned for its cost-efficient drug discovery model and robust clinical development capabilities, especially within China. Terns Pharmaceuticals is focused on developing a portfolio of small-molecule candidates tailored for non-alcoholic steatohepatitis (NASH), oncology, and obesity.
One of the company's flagship programs is the TERN-501, an investigational orally administered thyroid hormone receptor-β (THR-β) agonist aimed at treating NASH. The Phase 2a DUET clinical trial revealed promising results, showing significant impacts on liver fat content and fibro-inflammation markers within a short period. This positions TERN-501 as a potential leading therapy for NASH.
Additionally, Terns is developing TERN-701, an allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML), and TERN-601, a small-molecule GLP-1 receptor agonist for obesity. Both candidates have shown encouraging preclinical and early clinical data, promising significant advancements in their respective fields.
Financially, as of the latest quarter, Terns Pharmaceuticals reported cash, cash equivalents, and marketable securities amounting to $266.6 million, supporting the planned operating expenses into 2026. Recent clinical trials and corporate updates highlight the company's ongoing dedication to addressing global health challenges through innovative drug development.
For more information, please visit their website at www.ternspharma.com.
Terns Pharmaceuticals reported positive results from the Phase 2a LIFT clinical trial of TERN-101, an FXR agonist for NASH treatment. The trial demonstrated no discontinuations due to adverse events, including pruritus, and significant improvements in corrected T1 (cT1), a liver inflammation and fibrosis marker. After 12 weeks, significant changes in cT1 were observed in the 10 mg and 15 mg groups compared to placebo. Terns plans a combination trial of TERN-101 with TERN-501 in early 2022, following these promising outcomes.
Terns Pharmaceuticals, Inc. (Nasdaq: TERN) announced a conference call to discuss new top-line data from the Phase 2a LIFT study evaluating TERN-101 in patients with non-alcoholic steatohepatitis (NASH). The call is scheduled for June 14, 2021, at 8:30 a.m. ET, with a live webcast available. Terns focuses on developing small-molecule therapies targeting NASH and chronic liver diseases, aiming to offer significant clinical benefits based on validated mechanisms of action. The details of the webcast and conference call are provided for interested stakeholders.
Terns Pharmaceuticals is set to present at the UBS Global Healthcare Virtual Conference on May 24, 2021, at 12:00 p.m. ET, followed by participation in the J.P. Morgan Biotech 2021 CEO Conference Call Series on May 25, 2021, at 1:00 p.m. ET. A live audio webcast will be accessible on the company’s investor page, with a 30-day archive available post-event. Terns specializes in developing small-molecule therapy candidates for non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. For more details, visit their official website.
Terns Pharmaceuticals reported Q1 2021 financial results and corporate updates, highlighting advancements in their NASH clinical programs. With top-line data for the Phase 2a LIFT study of TERN-101 expected in June 2021, the company emphasizes the focus on safety and multiple non-invasive endpoints. The oversubscribed IPO raised $147 million, enhancing their financial position. R&D expenses rose to $8.7 million, while the net loss increased to $13.3 million from $9.2 million a year earlier. Cash reserves of $195.6 million are projected to support operations through 2024.
On April 7, 2021, Terns Pharmaceuticals, a clinical-stage biopharmaceutical firm, announced its participation in the 19th Annual Virtual Needham Healthcare Conference. The presentation is set for April 14 at 11:40 a.m. ET. Interested parties can access a live audio webcast through the conference and Terns’ website, with a replay available for 30 days post-event. Terns focuses on developing small-molecule therapies for non-alcoholic steatohepatitis (NASH) and chronic liver diseases, utilizing clinically validated mechanisms to benefit patients.
Terns Pharmaceuticals reported a strong financial position with $75 million in cash as of Q4 2020, following an upsized IPO that raised approximately $147 million in February 2021. The company is advancing its pipeline for treating non-alcoholic steatohepatitis (NASH) with three clinical-stage candidates: TERN-101 (Phase 2a), TERN-201 (Phase 1), and TERN-501 (Phase 1). Key milestones include expected data readouts in mid-2021. The company reduced total net loss to $40.6 million from $68.8 million in 2019, indicating improved cost management.
Terns Pharmaceuticals has initiated dosing in a Phase 1 clinical trial for TERN-501, a selective thyroid hormone receptor beta (THR-β) agonist targeting non-alcoholic steatohepatitis (NASH). Designed for high metabolic stability and enhanced liver distribution, TERN-501 aims to demonstrate improved safety and efficacy compared to other THR-β agonists. The trial, involving approximately 90 participants, will assess safety, tolerability, pharmacokinetics, and pharmacodynamic biomarkers, with initial top-line data expected in the second half of 2021.
Terns Pharmaceuticals, Inc. (Nasdaq: TERN) will present data on its NASH clinical programs at the NASH-TAG Conference 2021 from March 11-13. The company will give an oral presentation on targeting vascular adhesion protein-1 (VAP-1) inhibition for NASH treatment and showcase its FXR agonist, TERN-101. The oral presentation is scheduled for March 13 at 6:45 PM MST. Terns aims to initiate a Phase 1b trial for TERN-201 in patients in H1 2021 and expects Phase 2a data for TERN-101 by Q3 2021. Both therapies target chronic liver diseases, aiming for significant clinical benefits.
Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage biopharmaceutical company, announced its participation in the Cowen 41st Annual Health Care Conference. Management will present on March 4 at 9:50 a.m. ET, with a live audio webcast available on their website. Additionally, Terns will join a NASH panel discussion on March 2 from 12:50-1:50 p.m. ET. The company focuses on developing small-molecule therapies for non-alcoholic steatohepatitis (NASH) and chronic liver diseases.
Terns Pharmaceuticals, Inc. (Nasdaq: TERN) has successfully closed its initial public offering of 7,500,000 shares at $17.00 each. Additionally, underwriters exercised their option to purchase 1,125,000 shares, leading to projected gross proceeds of approximately $146.6 million. This funding aims to support the development of Terns' pipeline targeting non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. The offering was facilitated by J.P. Morgan, Goldman Sachs & Co. LLC, and Cowen. The shares were registered with the SEC, and the entire offering is expected to close by February 12, 2021.
FAQ
What is the current stock price of Terns Pharmaceuticals (TERN)?
What is the market cap of Terns Pharmaceuticals (TERN)?
What does Terns Pharmaceuticals, Inc. specialize in?
Where is Terns Pharmaceuticals located?
What is TERN-501 and what disease does it target?
What are the main therapeutic areas Terns Pharmaceuticals focuses on?
What is the significance of TERN-701?
How is Terns Pharmaceuticals funded for its operations?
What recent achievement has Terns Pharmaceuticals made in clinical trials?
What is TERN-601 being developed for?
What is the main objective of Terns Pharmaceuticals?
Where can I find more information about Terns Pharmaceuticals' research and development activities?
